Carotid plaque thickness predicts cardiovascular events and death in patients with chronic kidney disease.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
31 Oct 2024
Historique:
received: 17 09 2023
accepted: 21 10 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 1 11 2024
Statut: epublish

Résumé

Classical risk scoring systems underestimate the risk of cardiovascular disease in chronic kidney disease (CKD). Coronary artery calcium score (CACS) has improved prediction of cardiovascular events in patients with CKD. The maximal carotid plaque thickness (cPTmax) measured in ultrasound scans of the carotid arteries has demonstrated similar predictive value as CACS in the general population. This is the first study to investigate whether cPTmax can predict cardiovascular events in CKD and to compare the predictive value of cPTmax and CACS in CKD. Two hundred patients with CKD stage 3 from the Copenhagen CKD Cohort underwent ultrasound scanning of the carotid arteries. The assessment consisted of locating plaque and measuring the thickest part of the plaque, cPTmax. Based on the distribution of cPTmax, the participants were divided into 3 groups: No plaques, cPTmax 1.0-1.9 mm and cPTmax > 1.9 mm (median cPTmax = 1.9 mm among patients with plaques). To measure CACS, 175 of the patients underwent a non-contrast CT scan of the coronary arteries. The follow-up time spanned between the ultrasound scan and a predefined end-date or the time of first event, defined as a composite of major cardiovascular events or death of any cause (MACE). The median follow-up time was 5.4 years during which 45 patients (22.5%) developed MACE. In a Cox-regression adjusted for classical cardiovascular risk factors, patients with cPTmax > 1.9 mm had a significantly increased hazard ratio of MACE (HR 3.2, CI: 1.1-9.3), p = 0.031) compared to patients without plaques. C-statistics was used to evaluate models for predicting MACE. The improvement in C-statistics was similar for the two models including classical cardiovascular risk factors plus cPTmax (0.247, CI: 0.181-0.312) and CACS (0.243, CI: 0.172-0.315), respectively, when compared to a model only controlled for time since baseline (a Cox model with no covariates). Our results indicate that cPTmax may be useful for predicting MACE in CKD. cPTmax and CACS showed similar ability to predict MACE.

Sections du résumé

BACKGROUND BACKGROUND
Classical risk scoring systems underestimate the risk of cardiovascular disease in chronic kidney disease (CKD). Coronary artery calcium score (CACS) has improved prediction of cardiovascular events in patients with CKD. The maximal carotid plaque thickness (cPTmax) measured in ultrasound scans of the carotid arteries has demonstrated similar predictive value as CACS in the general population. This is the first study to investigate whether cPTmax can predict cardiovascular events in CKD and to compare the predictive value of cPTmax and CACS in CKD.
METHOD METHODS
Two hundred patients with CKD stage 3 from the Copenhagen CKD Cohort underwent ultrasound scanning of the carotid arteries. The assessment consisted of locating plaque and measuring the thickest part of the plaque, cPTmax. Based on the distribution of cPTmax, the participants were divided into 3 groups: No plaques, cPTmax 1.0-1.9 mm and cPTmax > 1.9 mm (median cPTmax = 1.9 mm among patients with plaques). To measure CACS, 175 of the patients underwent a non-contrast CT scan of the coronary arteries. The follow-up time spanned between the ultrasound scan and a predefined end-date or the time of first event, defined as a composite of major cardiovascular events or death of any cause (MACE).
RESULTS RESULTS
The median follow-up time was 5.4 years during which 45 patients (22.5%) developed MACE. In a Cox-regression adjusted for classical cardiovascular risk factors, patients with cPTmax > 1.9 mm had a significantly increased hazard ratio of MACE (HR 3.2, CI: 1.1-9.3), p = 0.031) compared to patients without plaques. C-statistics was used to evaluate models for predicting MACE. The improvement in C-statistics was similar for the two models including classical cardiovascular risk factors plus cPTmax (0.247, CI: 0.181-0.312) and CACS (0.243, CI: 0.172-0.315), respectively, when compared to a model only controlled for time since baseline (a Cox model with no covariates).
CONCLUSION CONCLUSIONS
Our results indicate that cPTmax may be useful for predicting MACE in CKD. cPTmax and CACS showed similar ability to predict MACE.

Identifiants

pubmed: 39482658
doi: 10.1186/s12882-024-03831-4
pii: 10.1186/s12882-024-03831-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

389

Informations de copyright

© 2024. The Author(s).

Références

Hill NR, Fatoba ST, Oke JL, Hirst JA, Callaghan AO, Lasserson DS et al. Global prevalence of chronic kidney disease – A systematic review and Meta-analysis. 2016; 1–18. https://doi.org/10.5061/dryad.3s7rd.Funding
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52. https://doi.org/10.1016/S0140-6736(13)60595-4 .
doi: 10.1016/S0140-6736(13)60595-4 pubmed: 23727170
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2020;395:709–33. https://doi.org/10.1016/S0140-6736(20)30045-3 .
doi: 10.1016/S0140-6736(20)30045-3
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney Disease and the risks of Death, Cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. https://doi.org/10.1056/nejmoa041031 .
doi: 10.1056/nejmoa041031 pubmed: 15385656
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a Population with chronic kidney disease in a large Managed Care Organization. Arch Intern Med. 2004;164:659–63. https://doi.org/10.1001/archinte.164.6.659 .
doi: 10.1001/archinte.164.6.659 pubmed: 15037495
Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006;47:378–84. https://doi.org/10.1053/j.ajkd.2005.11.017 .
doi: 10.1053/j.ajkd.2005.11.017 pubmed: 16490615
Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol. 2017;2:635–43. https://doi.org/10.1001/jamacardio.2017.0363 .
doi: 10.1001/jamacardio.2017.0363 pubmed: 28329057 pmcid: 5798875
Lee JH, Rizvi A, Hartaigh B, Han D, Park MW, Roudsari HM, et al. The predictive value of coronary artery calcium scoring for major adverse cardiac events according to renal function (from the Coronary computed tomography angiography evaluation for clinical outcomes: an International Multicenter [CONFIRM] Registry). Am J Cardiol. 2019;123:1435–42. https://doi.org/10.1016/j.amjcard.2019.01.055 .
doi: 10.1016/j.amjcard.2019.01.055 pubmed: 30850210
Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015;26:439–47. https://doi.org/10.1681/ASN.2014020173 .
doi: 10.1681/ASN.2014020173 pubmed: 25145930
Sørensen IMH, Bjergfelt SS, Hjortkjær HØ, Kofoed KF, Lange T, Feldt-Rasmussen B, et al. Coronary and extra-coronary artery calcium scores as predictors of cardiovascular events and mortality in chronic kidney disease stages 1–5: a prospective cohort study. Nephrol Dial Transpl. 2022;1–13. https://doi.org/10.1093/ndt/gfac252 .
Valdivielso JM, Betriu A, Martinez-Alonso M, Arroyo D, Bermudez-Lopez M, Fernandez E. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. PLoS ONE. 2017;12(10):e0186665. https://doi.org/10.1371/journal.pone.0186665 .
doi: 10.1371/journal.pone.0186665 pubmed: 29045466 pmcid: 5646852
Avramovski P, Avramovska M, Sikole A. B-flow imaging estimation of carotid and femoral atherosclerotic plaques: vessel walls rheological damage or strong predictor of cardiovascular mortality in chronic dialysis patients. Int Urol Nephrol. 2016;48:1713–20. https://doi.org/10.1007/s11255-016-1393-x .
doi: 10.1007/s11255-016-1393-x pubmed: 27515315
Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult americans. Eur Hear J - Cardiovasc Imaging. 2017;19:1042–50. https://doi.org/10.1093/ehjci/jex239 .
doi: 10.1093/ehjci/jex239
Bjergfelt SS, Sørensen IMH, Hjortkjær H, Landler N, Ballegaard ELF, Biering-Sørensen T, et al. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification. PLoS ONE. 2021;16:1–16. https://doi.org/10.1371/journal.pone.0260417 .
doi: 10.1371/journal.pone.0260417
Sørensen IMH, Saurbrey SAK, Hjortkjær HØ, Brainin P, Carlson N, Ballegaard ELF, et al. Regional distribution and severity of arterial calcification in patients with chronic kidney disease stages 1–5: a cross-sectional study of the Copenhagen chronic kidney disease cohort. BMC Nephrol. 2020;21:534. https://doi.org/10.1186/s12882-020-02192-y .
doi: 10.1186/s12882-020-02192-y pubmed: 33297991 pmcid: 7726904
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 .
doi: 10.7326/0003-4819-150-9-200905050-00006 pubmed: 19414839 pmcid: 2763564
Of OJOS, Kidney Disease. Improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:4–4. https://doi.org/10.1038/kisup.2012.76 .
doi: 10.1038/kisup.2012.76
Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N et al. Mannheim carotid intima-media thickness consensus (2004–2006): An update on behalf of the advisory board of the 3rd and 4th Watching the Risk Symposium 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23: 75–80. https://doi.org/10.1159/000097034
Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al. Recommendations for the Assessment of Carotid arterial plaque by Ultrasound for the characterization of atherosclerosis and evaluation of Cardiovascular Risk: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33:917–33. https://doi.org/10.1016/j.echo.2020.04.021 .
doi: 10.1016/j.echo.2020.04.021 pubmed: 32600741
Ferreira-Divino L. Association Between Carotid Artery Plaque and Albuminuria in Individuals With Type 2 Diabetes and No Clinical Cardiovascular Disease in: In: JASN, editor. Abstract Supplement - Kidney Week. 2022. p. 913. https://doi.org/10.1097/rhu.0b013e3182557a66
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–32. https://doi.org/10.1016/0735-1097(90)90282-T .
doi: 10.1016/0735-1097(90)90282-T pubmed: 2407762
Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to Predict Coronary Heart Disease events. Arch Intern Med. 2004;164:1285. https://doi.org/10.1001/archinte.164.12.1285 .
doi: 10.1001/archinte.164.12.1285 pubmed: 15226161
Wenning C, Vrachimis A, Pavenstädt HJ, Reuter S, Schäfers M. Coronary artery calcium burden, carotid atherosclerotic plaque burden, and myocardial blood flow in patients with end-stage renal disease: a non-invasive imaging study combining PET/CT and 3D ultrasound. J Nucl Cardiol. 2021;28:2660–70. https://doi.org/10.1007/s12350-020-02080-w .
doi: 10.1007/s12350-020-02080-w pubmed: 32140994
Gracia M, Betriu À, Martínez-Alonso M, Arroyo D, Abajo M, Fernández E, et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. 2016;11:287–96. https://doi.org/10.2215/CJN.01240215 .
doi: 10.2215/CJN.01240215 pubmed: 26668022
Palanca A, Castelblanco E, Perpiñán H, Betriu À, Soldevila B, Valdivielso JM, et al. Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes. Atherosclerosis. 2018;276:50–7. https://doi.org/10.1016/j.atherosclerosis.2018.07.018 .
doi: 10.1016/j.atherosclerosis.2018.07.018 pubmed: 30032025
Golan R, Shai I, Gepner Y, Harman-Boehm I, Schwarzfuchs D, Spence JD, et al. Effect of wine on carotid atherosclerosis in type 2 diabetes: a 2-year randomized controlled trial. Eur J Clin Nutr. 2018;72:871–8. https://doi.org/10.1038/s41430-018-0091-4 .
doi: 10.1038/s41430-018-0091-4 pubmed: 29379143
Mortensen MB, Fuster V, Muntendam P, Mehran R, Baber U, Sartori S, et al. A simple disease-guided Approach to personalize ACC/AHA-Recommended statin allocation in Elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68:881–91. https://doi.org/10.1016/j.jacc.2016.05.084 .
doi: 10.1016/j.jacc.2016.05.084 pubmed: 27561760
Stein JH, Smith SS, Hansen KM, Korcarz CE, Piper ME, Fiore MC, et al. Longitudinal effects of smoking cessation on carotid artery atherosclerosis in contemporary smokers: the Wisconsin smokers Health Study. Atherosclerosis. 2020;315:62–7. https://doi.org/10.1016/j.atherosclerosis.2020.11.010 .
doi: 10.1016/j.atherosclerosis.2020.11.010 pubmed: 33227549 pmcid: 7736540
Baber U, Mehran R, Sartori S, Schoos MM, Sillesen H, Muntendam P, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the bioimage study. J Am Coll Cardiol. 2015;65:1065–74. https://doi.org/10.1016/j.jacc.2015.01.017 .
doi: 10.1016/j.jacc.2015.01.017 pubmed: 25790876
Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart. 2013;99:365–72. https://doi.org/10.1136/heartjnl-2012-302818 .
doi: 10.1136/heartjnl-2012-302818 pubmed: 23118349

Auteurs

Sasha S Bjergfelt (SS)

Department of Nephrology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen, DK-2200, Denmark.

Ida M H Sørensen (IMH)

Department of Nephrology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.

Laerke Urbak (L)

Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.

Klaus F Kofoed (KF)

Department of Cardiology and Radiology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK- 2100, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen, DK-2200, Denmark.

Theis Lange (T)

Department of Public Health (Biostatistics), Faculty of Health and Medical Sciences, University of Copenhagen, Øster Farimagsgade 5, Copenhagen, DK-1014, Denmark.

Bo Feldt-Rasmussen (B)

Department of Nephrology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen, DK-2200, Denmark.

Henrik Sillesen (H)

Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.

Christina Christoffersen (C)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen, DK-2200, Denmark.
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK- 2100, Denmark.

Susanne Bro (S)

Department of Nephrology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. Susanne.Bro@regionh.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH